trial

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

NCTId NCT07116694
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 33 (actual)
Sponsored by BioXcel Therapeutics Inc
Primary completion 2025-10-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-06-19
Primary completion
2025-10-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
BXCL501 Sublingual Film

Sponsors

BioXcel Therapeutics IncLead Sponsor
Premier ResearchCollaborator

Investigators

1
Matt Mandel, MDStudy Chair

Sites

5 total
Chino, United StatesOceanside, United StatesOrange, United StatesSt Louis, United StatesLas Vegas, United States

Linked catalysts

1
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia — primary completion2025-10-07

Facts & assertions

4 sourced
Enrollment
33
Phase
PHASE2
Primary Completion Date
2025-10-07
Status
COMPLETED
relationships
The graph out of here
drug
BXCL501 Sublingual Film
drug
lead_sponsor
BioXcel Therapeutics Inc
company
collaborator
Premier Research
company
indication
Bipolar Disorder
indication
Psychomotor Agitation
indication
Schizophreniform Disorders
indication
investigator
Matt Mandel, MD
person